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United KingdomBackground There is strong evidence of an association between chronic kidney disease (CKD) and cardiovascular
disease. To date, however, proof that a reduction in glomerular filtration rate (GFR) is a causative factor in cardiovascular
disease is lacking. Kidney donors comprise a highly screened population without risk factors such as diabetes and
inflammation, which invariably confound the association between CKD and cardiovascular disease. There is strong evidence
that increased arterial stiffness and left ventricular hypertrophy and fibrosis, rather than atherosclerotic disease, mediate the
adverse cardiovascular effects of CKD. The expanding practice of live kidney donation provides a unique opportunity to study
the cardiovascular effects of an isolated reduction in GFR in a prospective fashion. At the same time, the proposed study will
address ongoing safety concerns that persist because most longitudinal outcome studies have been undertaken at single centers
and compared donor cohorts with an inappropriately selected control group.
Hypotheses The reduction in GFR accompanying uninephrectomy causes (1) a pressure-independent increase in aortic
stiffness (aortic pulse wave velocity) and (2) an increase in peripheral and central blood pressure.
Methods This is a prospective, multicenter, longitudinal, parallel group study of 440 living kidney donors and 440
healthy controls. All controls will be eligible for living kidney donation using current UK transplant criteria. Investigations will be
performed at baseline and repeated at 12 months in the first instance. These include measurement of arterial stiffness using
applanation tonometry to determine pulse wave velocity and pulse wave analysis, office blood pressure, 24-hour ambulatory
blood pressure monitoring, and a series of biomarkers for cardiovascular and bone mineral disease.
Conclusions These data will prove valuable by characterizing the direction of causality between cardiovascular and
renal disease. This should help inform whether targeting reduced GFR alongside more traditional cardiovascular risk factors is
warranted. In addition, this study will contribute important safety data on living kidney donors by providing a longitudinal
assessment of well-validated surrogate markers of cardiovascular disease, namely, blood pressure and arterial stiffness. If any
adverse effects are detected, these may be potentially reversed with the early introduction of targeted therapy. This should
ensure that kidney donors do not come to long-term harm and thereby preserve the ongoing expansion of the living donor
transplant program (NCT01769924). (Am Heart J 2014;167:141-149.e2.)From the aBirmingham Cardio-Renal Group, Centre for Clinical Cardiovascular Science,
Nuffield House, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom,
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The robust epidemiologic evidence that shows chronic
kidney disease (CKD), as manifest by reduced estimated
glomerular filtration rate (eGFR), is associated with
increased cardiovascular morbidity and mortality pro-
vides a strong rationale for a prospective study to
determine the cardiovascular effects of kidney donation.
A graded inverse relationship exists between cardiovas-
cular risk and eGFR1; deleterious cardiovascular effects
are clearly evident once eGFR falls to b60 mL/min per
1.73 m2, although the exact threshold at which
cardiovascular risk becomes elevated remains conten-
tious.2,3 Although most data indicate that the cutoff lies
between 60 and 70 mL/min per 1.73 m2, it may be even
higher; in a meta-analysis of general population cohorts
with a median follow-up of about 8 years and more than 5
million person-years, mortality rose exponentially once
eGFR fell below 75 mL/min per 1.73 m2.
Every year, more than 6,000 US individuals undergo
elective nephrectomy for the purposes of live donation
without apparent increased long-term mortality or
cardiovascular risk.4,5 Uninephrectomy may be qualified
as an “acute kidney injury,” with an immediate 50%
reduction in GFR followed by an improvement related to
hypertrophy in the remaining kidney—but only to 60% to
70% of baseline.6 Up to two-thirds of donors after
nephrectomy fulfil the criteria for CKD stage 3 (eGFR,
30-59 mL/min per 1.73 m2) dependent on baseline age
and renal function,7 which has an approximate odds ratio
for cardiovascular disease of between 2 and 4 in the
general population.8 To date, however, all studies
examining the long-term consequences of kidney dona-
tion have been reassuring, often showing better health
outcomes in donors compared with the general popula-
tion.4,9,10 Small adverse cardiovascular effects of dona-
tion cannot be excluded, however, because of residual
confounding from selection and follow-up biases. Most
donors are highly motivated individuals, often making
healthy lifestyle choices both before and after nephrec-
tomy. This inherent altruistic nature, in conjunction with
the rigorous medical selection procedures for donors,
results in an extreme low-risk population, for whom it is
near impossible to identify a control cohort of equivalent
health status from the general population. This makes
well-controlled studies difficult, and thus, far we are
aware of only one published prospective, controlled
pathophysiologic study of kidney donors.11
The mechanisms by which CKD exerts adverse effects
on cardiovascular structure and function are diverse and
have been the subject of recent reviews.12,13 Leading
potential mediators include increased arterial stiffness,
hypertension, increased left ventricular (LV) mass and
abnormal bone mineral metabolism, which may lead to
increased vascular calcification.12 There is strong cross-
sectional evidence that aortic pulse wave velocity (aPWV;a validated measure of arterial stiffness) increases as GFR
falls.14-16 In a community-based study, among treated
hypertensive patients, even minimally impaired baseline
renal function was associated with an increased rate of
aortic stiffening.17 Aortic PWV is an independent
predictor of all-cause and cardiovascular mortality in
many populations including patients on dialysis,18,19 and
failure to lower aPWV by angiotensin-converting enzyme
inhibitors and blood pressure reduction has been
associated with reduced survival.20 To date, only one
study examining arterial stiffness in kidney donors after
nephrectomy has been published.21 This had a cross-
sectional observational design, comparing 101 kidney
donors at a mean of 111 ± 42 months from donation with
healthy controls matched only for age and gender,
indicating that aPWV was significantly higher in donors.
In a recent uncontrolled study of 17 donors, although
aPWV was not examined, augmentation index and
central arterial pressure were unchanged at 6 months
compared with baseline.22
With respect to the effects of kidney donation on
peripheral blood pressure, the data are inconclusive, but
the best available evidence from a meta-analysis suggests
a moderate increase of about 5 mm Hg in systolic
pressure at 10 years after donation.23 Although high-
quality prospective studies of donors are still required, in
the general population, even a 2-mm Hg increase in
systolic blood pressure is associated with a long-term
increase in mortality of about 10% for stroke and 7% for
ischemic heart disease.24 Thus, it appears that either the
adverse effects of hypertension in kidney donors are
small and as yet undetected by clinical end point studies
or that regular medical supervision postdonation has
allowed early initiation of antihypertensive therapy and
thereby prevented harmful sequelae.
Increased LV mass is an almost universal finding by late-
stage CKD25 and is recognized as an important mediator
of morbidity and mortality due to heart failure and lethal
arrhythmia, the commonest modes of death in CKD.26
Chronic Kidney Disease–Mineral and Bone Disorder
(CKD-MBD) is driven by impaired phosphate excretion
resulting in both bone disease and vascular calcification,
which, in turn, mediates increased arterial stiffness and
adverse LV remodeling.27,28 Markers of CKD-MBD such as
phosphate, fibroblast growth factor 23 (FGF-23), and
parathyroid hormone (PTH) predict mortality and ad-
verse cardiovascular events in patients with CKD.29
Furthermore, there is evidence from community-based
studies of graded associations between phosphate and LV
mass, cardiovascular events, and death.30 Further de-
tailed information is therefore required on the effect of
kidney donation on both LV mass and markers of CKD-
MBD. A 23% increase in PTH has already been reported in
kidney donors at 6 months after nephrectomy compared
with controls.11
Table I. Inclusion and exclusion criteria
Inclusion criteria
Age 18-80 y
Acceptable GFR by donor age before donation⁎
Exclusion criteria
Hypertensive end-organ damage, uncontrolled hypertension or the
requirement for N2 antihypertensive medications
Significant proteinuria†
LV dysfunction
Diabetes mellitus
Atrial fibrillation
Any history of cardiovascular or pulmonary disease that would preclude
kidney donation
⁎Based on the anticipation of having an eGFR of N50 mL/min per 1.73 m2 aged 70
years.
†ACR N30 mg/mmol, PCR N50 mg/mmol, or 24-hour total protein N300 mg/d.
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increased cardiovascular risk, this relationship may not be
causal: CKD has a powerful clustering effect for other
cardiovascular risk factors such as hypertension, diabetes,
dyslipidemia, and inflammation, which may confound the
association. Kidney donors provide an ideal “human
model” that enables the longitudinal study of the
cardiovascular effects of a reduction in GFR in isolation
without the multiple confounding factors associated with
renal disease. The proposed study will prospectively
examine the effects of unilateral nephrectomy on the
potential pathophysiologic mechanisms that appear to
mediate cardiovascular morbidity and mortality in CKD,
namely, arterial stiffness and blood pressure as primary
end points, and LV mass and CKD-MBD parameters as
nested substudies, in a cohort of kidney donors large
enough to allow the detection of small effect sizes.
Hypotheses
In living kidney donors, the reduction in GFR that
accompanies nephrectomy results in (1) a pressure-
independent increase in aortic stiffness (aPWV), (2) an
increase in blood pressure, (3) an increase in LV mass and
impairment in LV diastolic function, and (4) adverse
effects on bone mineral metabolism.Methods
Study design
This is a prospective, multicenter, longitudinal, parallel group
study of 440 living kidney donors and 440 healthy controls to be
recruited for 2 years with initial follow-up of 12 months. All
participants will undergo informed written consent in keeping
with the principles set out by the Declaration of Helsinki. The
EARNEST study received research ethics approval in February
2013. The study is funded by the British Heart Foundation and
registered with the US National Institutes of Health database
(NCT01769924).
Study population
The inclusion and exclusion criteria for both donor subjects
and controls are outlined in Table I and are identical to those
set by the UK living kidney donor guidelines compiled by the
Joint Working Party of The British Transplantation Society and
The Renal Association.31 The only inclusion criterion is that
donor subjects will be scheduled for nephrectomy for the
purpose of kidney donation. A carefully matched series of
control patients will be recruited from the same living donor
clinics at which subjects are identified, who, after screening,
are found to be fit for donation but do not proceed to surgery
(eg, because of arterial anatomy and immunologic mismatch).
If appropriate, donor-related family members will also be
invited to participate in the study as healthy controls to
provide a closely matched control population with equivalent
baseline health status to the donor cohort.
Participants will be recruited from the following core centers,
chosen because of their high numbers of live donor transplantsand strength in vascular research: (1) Queen Elizabeth Hospital
Birmingham, England; (2) Addenbrooke's Hospital, Cambridge,
England; (3) Western Infirmary Glasgow, England; (4) University
Hospital Coventry and Warwick, England; (5) Southmead
Hospital, Bristol, England; (6) Northern General Hospital,
Sheffield, England; and (7) Belfast City Hospital, Belfast, North
Ireland. This study remains open to the inclusion of additional
transplant centers from inside and outside the UK.
Study protocol
A flowchart of the study protocol is presented in the Figure.
Investigations will be performed in all participants at baseline in
controls and within the 6 weeks before nephrectomy in donors,
with subsequent follow-up studies performed at 12 months.
Kidney donors will undergo routine follow-up by their local
medical and surgical team with no alteration to normal care. No
restrictions will be made to the introduction of any treatment
including antihypertensive drugs. At baseline and follow-up
visits, body mass index (BMI), blood pressure, heart rate, and
any clinical events will be recorded.
Table II summarizes the main outcome variables of interest
and the relevant data collection methods. Office blood pressure
will be measured on 3 occasions using a validated automated
device. The first measurement will be made after at least 5
minutes of seated rest. Two further readings will be taken with
at least 1 minute between readings. All measurements will be
made from the nondominant arm using the same cuff size.
Participants will also undergo 24-hour ambulatory blood
pressure monitoring using a British Hypertension Society
validated oscillometric recorder (Mobil-O-Graph NG; IEM,
Stolberg, Germany), which will provide data on both peripheral
and central blood pressure.32,33
Pulse wave velocity. Aortic PWV is the current criterion
standard technique for measuring aortic stiffness.34 Subjects will
be studied in a quiet, temperature-controlled laboratory after 15
minutes of lying supine. Pulse wave velocity (SphygmoCor;
AtCor Medical, Sydney, Australia) will be determined by
sequential acquisition of pressure waveforms from the carotid
and femoral arteries by use of a high-fidelity micromanometer
(SPC-301; Millar Instruments, Houston, TX), as previously
described.35,36 The path length will be calculated by subtracting
the distance between the sternal notch and the carotid
Figure
EARNEST study timeline. Abbreviations: ABPM, ambulatory blood pressure monitoring; AIx, augmentation index; BP, blood pressure; CTX,
carboxy-terminal collagen cross-links; FeNa, fractional excretion of urinary sodium; Hb, hemoglobin; MRI, magnetic resonance imaging; NT-
proBNP, N-terminal prohormone of brain natriuretic peptide; OC, osteocalcin; OPG, osteoprotegerin; PO4, phosphate; P1NP, N-terminal
propeptides of type I procollagen; RANK-L, receptor activator of nuclear factor κB ligand.
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the femoral site.
Pulse wave analysis. Blood pressure measurement will
be repeated supine before undertaking applanation tonometry
to record high-fidelity arterial pressure waveforms from which
indices relating to large artery stiffness can be calculated. Central
pressure waveforms will be derived and analyzed using the
technique of pulse wave analysis, as previously described.35,37 A
micromanometer will be used to flatten but not occlude the radial
artery using gentle pressure. An averaged peripheral waveform
and corresponding central waveform will be generated after 11
seconds of data capture. The central waveform will then be
analyzed to determine the augmentation index (the difference
between the second and first peaks of the central pressure
waveform, expressed as a percentage of the pulse pressure) and
central aortic pressures. The method has been shown to be
reproducible in both healthy subjects and in patients with CKD.
Augmentation index and aPWV will also be recorded using
ambulatory measurements taken from the Mobilograph.38,39Training and reproducibility. Delegated study staff
will receive formal training in measurement techniques of
arterial stiffness and undertake a reproducibility and measure-
ment quality study before study commencement. Measurements
at each center will only be performed by dedicated staff who
have undergone this training. Equipment will be calibrated at
baseline and throughout the study at specific intervals.
Assessment of renal function. Isotopic GFR for
kidney donors will also be measured using the renal clearance
of 51Cr-EDTA.40 Kidney function in controls will be estimated
from serum creatinine measurement.41,42
Blood and urine. Routine hematologic and biochemical
parameters will be recorded, including hemoglobin, creatinine,
calcium, albumin, glucose, phosphate, and PTH. A series of
biomarkers will also be measured including N-terminal prohor-
mone of brain natriuretic peptide, uric acid, urinary albumin/
creatinine ratio (ACR), and fractional excretion of sodium.43-45
Long-term follow-up. Patients will also be asked to
consent to longitudinal follow-up using the NHS Health & Social
Table II. Summary of EARNEST outcome variables and data collection methods
Outcome Method
Primary outcomes
Aortic stiffness (aPWV) aPWV (SphygmoCor; AtCor Medical) will be performed after 15 min of supine rest using a high-fidelity
micromanometer (SPC-301; Millar Instruments), as previously described.34 Path length is taken as sternal
notch-to-femoral pulse distance minus sternal notch-to-carotid pulse distance.
Mean 24-h ambulatory peripheral and central
systolic blood pressure
Mean systolic blood pressure from the nondominant arm using a 24-h monitoring system (Mobil-O-Graph
NG; IEM). Readings taken every 30 min during the day (0800-2200) and every 60 min overnight
Secondary outcomes
Office systolic and diastolic blood pressure Three separate measurements taken after at least 5 min of seated rest using a BHS validated automated
device, mean of last 2 recorded
Other ambulatory blood pressure parameters Mean 24 h and daytime systolic and diastolic blood pressure, pulse pressure
New-onset hypertension Diagnosis is defined as new antihypertensive therapy and/or systolic blood pressure N135 mm Hg or
diastolic blood pressure N85 mm Hg during the daytime on 24-h ambulatory monitoring.
Augmentation index and central
hemodynamics
A micromanometer (SPC-301; Millar Instruments) will be used to flatten but not occlude the radial artery
using gentle pressure. An averaged peripheral waveform and corresponding central waveform will be
generated after 11 s of data capture. The central waveform will then be analyzed to determine
augmentation index and central aortic pressures.
Renal function Isotopic GFR using the renal clearance of 51Cr-EDTA will be measured in donors.
Bloods Hemoglobin, creatinine, calcium, albumin, glucose, phosphate, PTH, NT-proBNP, and uric acid
Urine ACR and fractional excretion of sodium
Abbreviations: BHS, British Hypertension Society; EDTA, ethylenediaminetetraacetic acid; NT-proBNP, N-terminal prohormone of brain natriuretic peptide.
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the patient status and tracking service to examine long-term
outcomes after the study ends.
The authors are solely responsible for the design and conduct
of this study, all study analyses, the drafting and editing of the
manuscript, and its final contents.
EARNEST substudies
The Chronic Renal Impairment in Birmingham–Kidney
Donor (CRIB-DONOR) study: a cardiac magnetic
resonance (CMR) and echocardiography study
Those participants enrolled into the study at Queen
Elizabeth Hospital Birmingham and some other centers
will undergo CMR imaging and echocardiography at
baseline and 12 months to determine the effects of
an isolated reduction in GFR on LV mass and
function as well as aortic compliance and endothelial
function (online Supplementary Table I). Arterial stiffness
and office and ambulatory blood pressure will also be
measured at 6 months (in addition to the baseline and 12-
month measurement required for EARNEST). This study
is registered separately with the US National Institutes of
Health database (NCT01028703) and has a current
recruitment target of 140 participants.
Cardiac magnetic resonance imaging. Cardiac
magnetic resonance imaging will be performed using a
1.5-T scanner (Magnetom Avanto; Siemens, Erlangen,
Germany). Serial contiguous short-axis cines will be
piloted from the vertical long-axis and horizontal long-
axis images of the left and right ventricles (electrocar-
diogram R-wave gated, steady-state free precession
imaging [True-FISP]; temporal resolution 40-50 ms,repetition time 3.2 ms, echo time 1.7 ms, flip angle 60°,
slice thickness 7 mm with 3-mm gap) in accordance with
previously validated methodology.46 Analysis will be
performed offline (Argus Software; Siemens) by a single
blinded observer for the assessment of ventricular
volumes (end-diastolic, end-systolic and stroke volumes),
function (ejection fraction), and LV mass.46,47 In the
determination of ventricular mass, volumes, and function,
as compared with transthoracic echocardiography, CMR
has higher interstudy reproducibility, thereby reducing
the number of participants required to adequately power
such studies.48 Aortic distensibility will be assessed at the
ascending aorta and proximal descending aorta at the
level of the pulmonary artery and the distal descending
aorta at the level of the diaphragm on held end-expiration
and calculated using previously validated formulae.49
Measurement of aortic distensibility using CMR has low
intraobserver variability and good reproducibility.50
Peripheral blood pressure will be performed synchro-
nously, in triplicate, at the brachial artery at the time of
scanning for determination of pulse pressure.
Dynamic tissue-tagging MRI allows direct noninvasive
assessment of regional systolic and diastolic function and
is a previously validated technique.51 Spatial modulation
of magnetization will be used to generate a uniform grid
pattern with 8-mm tag separation on the LV myocardium
at 3 short-axis sections (basal, mid, and apex) and the
horizontal long-axis image using a fast filed echo multi-
shot sequence (temporal resolution 40-50 ms, repetition
time 3.9 ms, echo time 4.4 ms, voxel size 1.8/1.3/6.0
mm3, flip angel 14°, tag grid angle 45° with slice
thickness 6 mm, and a minimum number of 15 phases
per cardiac cycle) with prospective electrocardiogram
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performed offline (CIMTag2D; University of Auckland,
New Zealand) for LV strain, strain rate, and torsion
calculation, as previously described.52
Flow-mediated dilatation of the brachial artery will
also be measured using magnetic resonance measure-
ment of brachial artery area before and after 5
minutes of arterial occlusion and also after 400-μg
glyceryl trinitrate (GTN) control.53 Brachial artery
measurements will be performed offline using semi-
automated contour tracking software (MATLAB
R2008b; MathWorks Inc, Natick, MA) calculating
flow-mediated dilatation as the proportional change
in artery diameter in response to hyperemia.54
Transthoracic echocardiography. A comprehensive
transthoracic echocardiogram (iE33; Philips, Eindhoven,
the Netherlands) will be performed at rest with the
subject in the left lateral decubitus position by a single
experienced sonographer using second harmonic imag-
ing and an S5-1 multifrequency transducer. All parameters
will be measured in triplicate and averaged as per the
American Society of Echocardiography guidelines.55
Analysis will be performed offline by a single blinded
observer on an Xcelera workstation (Philips). Ventricular
dimensions, wall thickness, chamber volumes, and stroke
volume will be determined using standard methods.56
Left ventricular diastolic function will be determined
using standard techniques.57 Peak systolic (s′), early
diastolic (e′), and late diastolic (a′) mitral annular
velocities will be measured at end-expiration at the
septal, lateral, inferior, and anterior LV walls with real-
time pulsed wave tissue Doppler imaging (TDI).58
Gray-scale images for 2-dimensional LV strain, strain
rate, and torsion will be acquired in cineloop format in
triplicate from the apical 4-, 2-, and 3-chamber views
and parasternal short-axis views at basal, mid, and
apical levels at end expiration at frame rates N70 Hz
for offline analysis using commercially available soft-
ware (QLAB; Philips). Myocardial contours will be
manually traced at end-systole, and the software will
then generate a region of interest over the myocardi-
um. This will enable frame-to-frame tracking of
ultrasonic speckles that change position according to
surrounding tissue motion throughout the cardiac
cycle. Peak systolic velocities, strain, strain rate,
rotation, and twist will be measured for each
myocardial segment in triplicate and averaged.
In those subjects with appropriate image quality,
transthoracic echocardiography will also be performed
during a progressive submaximal exercise test to
derive stress-related changes in LV systolic and diastolic
function using TDI and strain measures. Subjects will
be installed on a dedicated semisupine cycling
ergometer (Schiller ERG 911 BP/L, Baar, Switzerland).
After a 15-minute rest period, each subject will
undergo an exercise test that includes 3 workloadstages of 4-minute duration at 20%, 30%, and 40% of
their maximal aerobic power estimated via the Wasser-
man equation [(body mass (50.72 − 0.372 × age)) −
350]/10.3 and corrected for semisupine position (20%
removed from normal values).59,60
The KARMA study: effect of Kidney donAtion on
bone-mineRal Metabolism and Arterial stiffness
Participants enrolled into the study at Addenbrooke's
Hospital, Cambridge, will undergo a more detailed
biochemical assessment of the bone mineral axis together
with dual-energy x-ray absorptiometry (DEXA). It is
planned to recruit 99 participants for the KARMA study,
2 controls for every living donor (online Supplementary
Table II).
Dual-energy x-ray absorptiometry scan. Dual-
energy x-ray absorptiometry is a means of measuring
bone mineral density and soft tissue composition. A beam
of x-ray, filtered into 2 energy bands, passes through the
patient's body. When soft tissue absorption is subtracted
out, the bone mineral density can be determined from the
absorption by bone at each energy. Dual-energy x-ray
absorptiometry is the most widely used and most
thoroughly studied bone density measurement technol-
ogy. For kidney donors, DEXA scans of the total body,
hips, and lumbar spine scanning will be performed before
surgery and 1 year later. The total body scan will enable
any changes in muscle mass to be estimated and their
influence on bone density factored out of the bone
density analysis. The total effective dose of x-ray radiation
for the proposed scans will be approximately 4.5 μSv,
comparable with a daily background from atmospheric
sources of 6 μSv. Pregnancy testing (urinary β-human
chorionic gonadotropin) will be performed in female
participants of childbearing age in the donor group
before DEXA scanning.
Blood tests
These will be the same as for the main EARNEST study,
but for kidney donors, additional samples will be taken at
days 1, 2, and 3 postoperatively and 6 weeks after
donation. Blood samples will be centrifuged within 30
minutes of venesection, and serum and plasma were
separated and frozen at −70°C. Samples will later also be
used for testing of vitamin D metabolites (1, 25-, and 25-
vitamin D), FGF-23, Klotho, PTH, osteoprotegerin, recep-
tor activator of nuclear factor κB ligand, bone remodeling
markers (carboxy-terminal collagen cross-links, N-terminal
propeptides of type I procollagen, osteocalcin), and
Fetuin-A as well as renin and aldosterone.
Urine tests. Again, these will be the same as for
the main EARNEST study, but in addition for
kidney donors, 100 mL aliquots of urine will be taken at
days 1, 2, and 3 postoperatively and 6 weeks after surgery
and frozen at −70°C for later measurement of Fetuin-A,
calcium, and phosphate.
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The formal comparison between arms of each of the
coprimary end points will use a linear regression model
on the within-patient change from baseline, adjusting for
baseline value, sex, ethnicity, use of antihypertensives,
age, eGFR at donation (and iGFR where available in
donors), and the other coprimary end point at baseline.
To formally control the overall significance level over
both coprimary end points (aPWV and blood pressure) at
5%, a Holm-Bonferroni method will be used. Findings will
be interpreted taking into consideration that aPWV and
blood pressure are correlated. A secondary analysis of the
coprimary end points will be performed according to age,
ethnic group, baseline eGFR and change in eGFR (and
isotopic GFR where available in donors), BMI, and
predonation hypertension.
EARNEST power calculations and sample size
Assuming that the SD of the within-patient change is 1.0
m/s in aPWV and 10 mm Hg in blood pressure,35,61 a
sample size of 800 patients (control and donors, 400
subjects each, assuming 9% dropout) will provide 80%
power to detect a difference of 0.22 m/s or 2.2 mm Hg
for aPWV and blood pressure, respectively, under a
2-sided t test at the 2.5% significance level.
Power calculations for CRIB-DONOR and KARMA sub-
studies are outlined in the online Appendix.
Discussion
There is strong evidence that patients with CKD have
increased cardiovascular risk with a graded relation with
both eGFR and the level of albuminuria.62 However,
previous studies are limited by their cross-sectional and
observational nature, and causation has not yet been
established. The true impact of CKD on the cardiovascu-
lar system remains hard to define because the duration of
the CKD is often unknown, the underlying causes are
diverse, and there are numerous confounders including
associated diseases such as hypertension and diabetes.
Moreover, the level of GFR at which adverse structural
and functional changes occur within the heart and
vasculature and at which cardiovascular risk starts to
rise is not clear. Kidney donors provide a unique healthy
population who change at a known time point from
having normal to impaired renal function. This study
should establish whether reduced GFR leads directly to
adverse cardiovascular effects such as increased arterial
stiffness, hypertension, LV mass, and mineral bone
disorder. Because the prevalence of CKD is high and
rising (14.0% in the United States in 2005-2010, as defined
by eGFR b60 mL/min per 1.72 m2 or ACR≥30 mg/g),26 it
is important to establish if a causal relationship exists to
determine whether targeting CKD alongside more
traditional risk factors could lead to reductions in
cardiovascular mortality and morbidity. The potentialsize of this effect is salutary. If causative, it has
been estimated that up to 10% of vascular events in
middle age and 20% in old age might be attributable to
reduced eGFR.63
By careful prospective measurement of ambulatory
blood pressure in living kidney donors before and after
nephrectomy, this study will also provide important
practical information needed for patient care. By
clarifying whether there is an increased frequency of
hypertension and surrogate markers of cardiovascular
disease after donation, we will be able to better advise
potential donors in future and inform national guidance
on the importance of long-term follow-up.
In an attempt to reduce the shortfall in the number of
organs available for transplantation, the opportunity to
undergo donor nephrectomy is now being offered to
people with preexisting medical conditions, which
include hypertension and raised BMI, as well as to subjects
who are older with lower baseline GFR. The potential
renal and cardiovascular risks of kidney donation may be
most relevant to this group of donors, but those studies
that have attempted to address this issue are single-center,
retrospective reports offering conflicting data.64-66 There
may also be increased risk in nonwhite donors, although
the data in this area remain preliminary.9 The EARNEST
study is large enough to prospectively examine the
influences of age, BMI, ethnicity, and comorbidity on
changes in cardiovascular structure and function after
nephrectomy in kidney donors.
We believe that the living kidney donation program is a
vital method of providing renal replacement therapy for
individuals with end-stage kidney disease. The evidence
to date suggests that this practice is safe, although there
are data demonstrating an increased risk of high blood
pressure after donation. Studying vascular parameters in
detail both before and after donation provides an
excellent opportunity to examine prospectively the
direction of causality between loss of kidney function
and cardiovascular disease. In addition, we may be able to
provide important information to guide the long-
term management of kidney donors. An open, critical
approach is vital if we are to preserve public trust
and the altruistic goodwill of donors, with the aim of
safeguarding the expansion of the living kidney
transplant program.Acknowledgements
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CRIB-DONOR power calculations and sample size
The major end point on which sample size and power for
the CRIB-DONOR study have been calculated is LV mass.Supplementary Table I. Summary of CRIB-DONOR study main outco
Outcome
Primary outcomes
LV mass Images acquired using 1.5-T CMR
offline (Argus Software; Siemens)
Aortic stiffness (aPWV) As for EARNEST, see Table II.
Secondary outcomes
New-onset hypertension As for EARNEST, see Table II.
Augmentation index and central
hemodynamics
As for EARNEST, see Table II.
LV systolic and diastolic function Myocardial tagging (SPAMM) wil
offline by a single blinded observe
Transthoracic echocardiography w
single blinded observer on an Xce
Endothelial function Magnetic resonance imaging (Ma
proportional change in artery dia
semiautomated contour tracking s
Exercise-induced changes in LV
strain and diastolic function
Progressive submaximal exercise t
using TDI and strain measures. Su
(Schiller ERG 911 BP/L).
Bloods As for EARNEST, see Table II.
In addition: biomarkers of oxidati
Urine As for EARNEST, see Table II.
SPAMM, Spatial modulation of magnetization imaging.
Supplementary Table II. Summary of KARMA study main outcome va
Outcome
Aortic stiffness (aPWV) As for EARNEST, see Table II.
New-onset hypertension As for EARNEST, see Table II.
Augmentation index and central
hemodynamics
As for EARNEST, see Table II.
Bone mineral density Kidney donor participants will undergo DEXA s
body, hips, and lumbar spine at baseline and
estimated and their influence factored out of th
Bloods As for EARNEST, see Table II.
In addition: vitamin D metabolites (1, 25-, an
markers (CTX, P1NP, OC), and Fetuin-A
Urine As for EARNEST, see Table II.
In addition: Fetuin-A, fractional excretion of ca
Abbreviations: OPG, Osteoprotegerin; RANK-L, receptor activator of nuclear factor κB ligand
procollagen; OC, osteocalcin.Assuming an SD of the within-patient change in LV mass
index of 12 g/m2,67 a sample size of 63 subjects per group
will provide N95% power to detect a change in LV mass
index of 7.5 g/m2 with an α value of .05. We are, therefore,
aiming to recruit 70patients per group to allow for dropouts.me variables and data collection methods
Method
imaging (Magnetom Avanto; Siemens). Analysis will be performed
by a single blinded observer.
l be performed on magnetic resonance images and analysis performed
r (CIMTag2D; University of Auckland).
ill be undertaken (iE33; Philips) and analysis performed offline by a
lera workstation (Philips).
gnetom Avanto; Siemens) to calculate flow-mediated dilatation as the
meter in response to hyperemia. Analysis will be performed offline using
oftware (MATLAB R2008b; MathWorks Inc).
esting to derive stress-related changes in LV systolic and diastolic function
bjects will be installed on a dedicated semisupine cycling ergometer
ve stress, endothelial function, collagen turnover
riables and data collection methods
Method
canning (Lunar Prodigy Advance; GE Healthcare, Bedford, UK) of the total
1 y. The total body scan will enable any changes in muscle mass to be
e bone density analysis.
d 25-vitamin D), FGF-23, Klotho, PTH, OPG, RANK-L, bone remodeling
lcium, phosphate
; CTX, carboxy-terminal collagen cross-links; P1NP, N-terminal propeptides of type I
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KARMA was planned as a descriptive study of the
changes in CKD-MBD parameters after kidney donation
based on the potential number of participants available at
the local center. The sample size determined was 33 kid-
ney donors with 33 matched controls and a further com-
parison group consisting of 33 general population controls.Supplementary Reference67. Edwards NC, Steeds RP, Stewart PM, et al. Effect of
spironolactone on left ventricular mass and aortic stiffness in
early-stage chronic kidney disease: a randomized
controlled trial. J Am Coll Cardiol 2009;
54(6):505-12.
